---
layout: default
title: Cetuximab
parent: Model Prediction Only (L5)
nav_order: 177
evidence_level: L5
indication_count: 10
---

# Cetuximab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Cetuximab: From Colorectal and Head and Neck Cancer to Childhood Bronchial Adenomas/Carcinoids

## One-Sentence Summary

Cetuximab is an EGFR-targeting monoclonal antibody that is generally used in colorectal and head and neck cancers. The TxGNN model predicts it may be effective for **childhood bronchial adenomas/carcinoids**. Currently **0 clinical trials** and **0 publications** support this prediction, so it rests on the model score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the Canadian licence data; cetuximab is generally used for colorectal and head and neck cancer |
| Predicted New Indication | Bronchial adenomas/carcinoids, childhood |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, cetuximab is an anti-EGFR antibody, its efficacy in EGFR-driven cancers such as colorectal and head and neck cancer is established, and mechanistically it might be applicable to other tumours that depend on EGFR signalling.

For this prediction, that link is weak. Bronchial carcinoids are neuroendocrine tumours with no established EGFR dependence, and no study retrieved connects cetuximab to this disease. The high score (99.95%) reflects knowledge-graph proximity, not biological or clinical confirmation. Treat it as a hypothesis only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2271249 | ERBITUX | — | — |

The licence record has no dosage form, manufacturer or indication text.

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Infusion reactions, skin toxicity (rash) and electrolytes, especially magnesium; refer to the package insert for the full list |
| Handling Protection | Please refer to the package insert and institutional policy for antineoplastic biologics |

Rash, hypomagnesaemia and infusion reactions are the main toxicities noted in the evidence pack for this drug. They would be a significant barrier in any long-term use.

---

## Safety Considerations

Please refer to the package insert for safety information. No drug-interaction records were found.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the model score, with no trials or publications. There is also no plausible EGFR-based rationale for childhood bronchial carcinoids. The gap in Canadian safety labelling data also blocks any safety screening.

**To proceed, the following is needed:**
- Any preclinical or clinical evidence of EGFR expression or dependence in bronchial carcinoids
- Mechanism of action data (DrugBank)
- Health Canada package insert warnings and contraindications
- Paediatric safety and dosing information, since the target population is children

**Note:** Two other predictions for cetuximab in this pack have stronger support and are better candidates for follow-up. Both are rated L3 (research question). They are **cystic neoplasm**, with Phase 1/2 trials in adenoid cystic carcinoma and salivary gland literature, and **pre-malignant neoplasm**, with a Phase 2 trial in high-risk pre-malignant upper aerodigestive lesions (NCT00524017) and an EGFR chemoprevention review.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

